Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience

Montori, Giulia; Catena, Fausto; Fugazzola, Paola; Ceresoli, Marco; Tomasoni, Matteo; Rubicondo, Carolina; Raimondo, Stefano; Pinelli, D.; Colledan, M.; Frigerio, Luigi; Ansaloni, Luca

doi:10.21037/jgo.2017.12.04

Cited by 11 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34,[39][40][41][42][43]45,47,48,50,53 Many studies reported that additional procedures were needed to manage complications. 34,40,41,44,46,47,49,50,53,54 Given the risks associated with HIPEC, prospective studies have focused on using HIPEC immediately after debulking (as part of the same procedure) in patients with high-volume intraperitoneal disease (FIGO stage III-IV at diagnosis or recurrence), particularly those with peritoneal carcinomatosis, who are at risk for widespread residual microscopic disease even after resection to no visible disease. Compared with postoperative intraperitoneal therapy, intraoperative intraperitoneal administration may enable better perfusion of the peritoneal space because adhesions will not yet have formed.…”

Section: Hyperthermic Intraperitoneal Chemotherapy At the Time Of Idsmentioning

confidence: 99%

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Armstrong

Alvarez

Bakkum-Gamez³

et al. 2019

Journal of the National Comprehensive Cancer Network

222

212

View full text Add to dashboard Cite

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.

show abstract

Section: Hyperthermic Intraperitoneal Chemotherapy At the Time Of Idsmentioning

confidence: 99%

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Armstrong

Alvarez

Bakkum-Gamez³

et al. 2019

Journal of the National Comprehensive Cancer Network

222

212

View full text Add to dashboard Cite

show abstract

“…However, the value of HIPEC in gastric cancer is controversial, It has reported CRS plus HIPEC yield fewer benefits in patients with PM from gastric cancer, and the median OS in GC is shorter than in other malignancies such as colorectal cancer, ovarian cancer, and appendicular cancer. [30,31] And clinical usefulness of systemic chemotherapy and HIPEC is judged to be moderate to high for PM of ovarian and colorectal origin but moderate to poor for gastric origin. [32] Contrast to these studies, the above studies mainly targeted the advanced gastric cancer with peritoneal metastasis, while, we aimed each stage of gastric cancer, and our IPHP procedure was not combined with chemotherapeutic agent, which may increase morbidity of adverse event.…”

Section: Discussionmentioning

confidence: 99%

Postoperative intraperitoneal hyperthermic perfusion improve survival for advanced gastric cancer

et al. 2019

View full text Add to dashboard Cite

To evaluate the value of intraperitoneal hyperthermic perfusion (IPHP) in the treatment of gastric cancer. Gastric cancer (GC) is a malignancy with poor prognosis, recent years have demonstrated advances in the use of IPHP for the treatment of advanced gastric cancer (AGC), but the outcome is controversial. Between January 2015 and January 2017, 134 patients with GC were treated with IPHP in our surgery department, 130 of them were advanced GC patients, and other 1439 cases were treated without IPHP for comparison. In this retrospective cohort study, demographic, perioperative data, and follow-up data were analyzed by univariant analysis, Kaplan–Meier and Cox regression survival analysis. We found the 1-year survival in IPHP group was significantly longer than it in non-IPHP group (85.5% vs 73.8%, P = .027). and IPHP decreased mortality 1.8 times in 2-year course (OR = 0.556, P = .004). The incidence rate of total complications in IPHP group was similar to that in the Non-IPHP group (6.67% vs 7.46%, respectively; P = .718). We classified all patients into four groups, operation alone, operation + chemotherapy, operation + IPHP, and operation + IPHP + chemotherapy. The 1-year survival in the groups was 70.2%, 77.5%, 83.1%, and 93.5%, respectively ( P = .001), compared with the group of operation alone, the 2-year mortality risk was decreased 1.76 times (OR = 0.569, P = .030) and 2.59 times (OR = 0.385, P = .022) in operation + IPHP group and operation + IPHP + chemotherapy group. Our results suggest that IPHP could contribute to improve survival of patients with gastric cancer. And the modality of operation + IPHP + chemotherapy is the optimal treatment modality for gastric cancer.

show abstract

“…The mainstay treatment for secondary peritoneal cancer is cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) [3][4][5][6]. Studies have revealed the improved survival rates of patients who received CRS + HIPEC treatment [7][8][9]. However, CRS + HIPEC treatment is a complex surgical procedure that commonly requires a long operation duration and causes significant surgical injuries.…”

Section: Introductionmentioning

confidence: 99%

Postoperative pain pathophysiology and treatment strategies after CRS + HIPEC for peritoneal cancer

Wang

2020

World J Surg Onc

View full text Add to dashboard Cite

Background: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment choice for peritoneal cancer. However, patients commonly suffer from severe postoperative pain. The pathophysiology of postoperative pain is considered to be from both nociceptive and neuropathic origins. Main body: The recent advances on the etiology of postoperative pain after CRS + HIPEC treatment were described, and the treatment strategy and outcomes were summarized. Conclusion: Conventional analgesics could provide short-term symptomatic relief. Thoracic epidural analgesia combined with opioids administration could be an effective treatment choice. In addition, a transversus abdominis plane block could also be an alternative option, although further studies should be performed.

show abstract

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience

Cited by 11 publications

References 30 publications

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Postoperative intraperitoneal hyperthermic perfusion improve survival for advanced gastric cancer

Postoperative pain pathophysiology and treatment strategies after CRS + HIPEC for peritoneal cancer

Contact Info

Product

Resources

About